- Home
- FIGS vs HROW Comparison
FIGS vs HROW Comparison
Compare FIGS & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- HROW
- Stock Information
- Founded
- FIGS 2013
- HROW 1998
- Country
- FIGS United States
- HROW United States
- Employees
- FIGS N/A
- HROW N/A
- Industry
- FIGS Apparel
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- HROW Health Care
- Exchange
- FIGS Nasdaq
- HROW Nasdaq
- Market Cap
- FIGS 1.2B
- HROW 1.4B
- IPO Year
- FIGS 2021
- HROW N/A
- Fundamental
- Price
- FIGS $9.62
- HROW $38.93
- Analyst Decision
- FIGS Hold
- HROW Strong Buy
- Analyst Count
- FIGS 5
- HROW 8
- Target Price
- FIGS $8.60
- HROW $68.86
- AVG Volume (30 Days)
- FIGS 2.7M
- HROW 753.2K
- Earning Date
- FIGS 11-06-2025
- HROW 11-10-2025
- Dividend Yield
- FIGS N/A
- HROW N/A
- EPS Growth
- FIGS 91.65
- HROW N/A
- EPS
- FIGS 0.11
- HROW N/A
- Revenue
- FIGS $581,034,000.00
- HROW $250,042,000.00
- Revenue This Year
- FIGS $4.73
- HROW $43.92
- Revenue Next Year
- FIGS $3.67
- HROW $41.22
- P/E Ratio
- FIGS $91.90
- HROW N/A
- Revenue Growth
- FIGS 5.90
- HROW 47.83
- 52 Week Low
- FIGS $3.57
- HROW $20.85
- 52 Week High
- FIGS $10.24
- HROW $50.72
- Technical
- Relative Strength Index (RSI)
- FIGS 65.50
- HROW 50.36
- Support Level
- FIGS $8.95
- HROW $36.95
- Resistance Level
- FIGS $10.24
- HROW $41.24
- Average True Range (ATR)
- FIGS 0.52
- HROW 2.66
- MACD
- FIGS 0.04
- HROW 0.39
- Stochastic Oscillator
- FIGS 77.66
- HROW 68.44
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.